Adenocarcinoma de recto y ano en paciente con enfermedad de Crohn tratado con infliximab Adenocarcinoma of the rectum and anus in a patient with Crohn´s disease treated with infliximab

Adenocarcinoma de recto y ano en paciente con enfermedad de Crohn tratado con infliximab Adenocarcinoma of the rectum and anus in a patient with Crohn´s disease treated with infliximab

In the present paper, we report the case of a patient with long-standing Crohn´s disease and multiple complications that, after receiving treatment with infliximab, was diagnosed with an adenocarcinoma of the rectum and anus that required radical surgery, later presenting multiple metastases. In the...

Full description

Bibliographic Details
Main Authors:	J. Egea Valenzuela, E. Belchí Segura, N. Essouri, A. Sánchez Torres, F. Carballo Álvarez
Format:	Article
Language:	English
Published:	Aran Ediciones 2010-08-01
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	Enfermedad de Crohn Cáncer colorrectal Infliximab Crohn´s disease Colorectal cancer
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010000800009

Similar Items

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Retreatment and maintenance therapy with infliximab in fistulizing Crohn' disease Retratamiento y tratamiento de mantenimiento con infliximab en la enfermedad de Crohn fistulizante
by: L. Rodrigo, et al.
Published: (2004-08-01)

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante
by: M. Luna-Chadid, et al.
Published: (2004-06-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
by: George Alex, et al.
Published: (2013-10-01)

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report
by: Zhijie Lv, et al.
Published: (2021-04-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice Infliximab mejora la calidad de vida en pacientes con enfermedad de Crohn fistulosa
by: V. Cadahia, et al.
Published: (2004-06-01)

Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
by: Yizhong Wang, et al.
Published: (2021-01-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
by: Akihiro Koga, et al.
Published: (2018-04-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
by: Hye-In Jung, et al.
Published: (2021-01-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy
by: Manzurul Chowdhury, et al.
Published: (2009-07-01)

Infliximab-induced psoriasis in a patient with crohn′s disease
by: Iqbal Bukhari, et al.
Published: (2015-01-01)

Infliximab- and Immunosuppressant-Resistant Crohn’s Disease Successfully Treated with Adsorptive Granulocyte Apheresis Combined with Prednisolone
by: Munenori Itagaki, et al.
Published: (2012-02-01)

Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease
by: Michał Sobjanek, et al.
Published: (2014-03-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn’s Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab
by: Mia Bendix, et al.
Published: (2020-11-01)

Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn’s Disease during One-Year Follow-Up
by: Mia Bendix, et al.
Published: (2021-03-01)

Anti-TNF treatment and miliary tuberculosis in Crohn’s disease
by: Milenković Branislava, et al.
Published: (2011-01-01)

A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease
by: Li Li, et al.
Published: (2021-07-01)

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
by: Yueying Chen, et al.
Published: (2021-04-01)

Arteritic anterior ischemic optic neuropathy (AAION) in a patient with Crohn´s disease treated with Infliximab.
by: Elisabet Martín García, et al.
Published: (2016-10-01)

Is safety infliximab during pregnancy in patients with inflammatory bowel disease? ¿El tratamiento con infliximab es seguro durante el embarazo en pacientes con enfermedad inflamatoria intestinal?
by: Federico Argüelles-Arias, et al.
Published: (2012-02-01)

EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN
by: E. G. Tsimbalova, et al.
Published: (2012-01-01)

Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients
by: Chen Yueying, et al.
Published: (2021-10-01)

Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease
by: Johanna Schoehl, et al.
Published: (2016-10-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Infliximab‐induced autoimmune hepatitis requiring liver transplantation
by: Frederick Wong, et al.
Published: (2019-11-01)

Crohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab
by: Aasem Abu Shtaya, et al.
Published: (2021-02-01)

Infliximab-related tubercular spinal epidural abscess without osseous involvement in a patient with Crohn’s disease: A case report
by: Phani Kiran Surapuraju, et al.
Published: (2021-01-01)

Crohn S Disease and Acne Fulminans as Associated Disoders (Case Report)
by: Pecova K, et al.
Published: (2015-09-01)

Cannot write session to /tmp/vufind_sessions/sess_fsm1s9fnp8lha6rst192nv9028